HAEMONETICS CORP — Director's Dealing 2025

Jul 25, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2025-07-24

Reporting Person: Pomeroy Claire (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-24	Common Stock	A	2693	—	Acquired	16872	Direct

Footnotes

F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.